STRIKE

Comprehensive STRategIes to tacKlE malignant tumors: from nanomedicine and theranostic to precision medicine

Principal Investigator: Monica Montesi
Involved personnel: Silvia Panseri, Giada Bassi, Arianna Rossi, Mohamed Saqawa

Starting date: 01/01/2023
Duration: 48 mesi
Total funding: 2.106.835,20 €
Call/Action: HORIZON-MSCA-2021-DN-01 / HORIZON-TMA-MSCA-DN
Coordinator: Anna Piperno (Università di Messina)
Consortium: UNIVERSITA DEGLI STUDI DI MESSINA (UNIME) Italy, CONSIGLIO NAZIONALE DELLE RICERCHE (CNR) Italy, NATIONAL UNIVERSITY OF IRELAND MAYNOOTH (NUIM), Ireland, UNIVERZITA PALACKEHO V OLOMOUCI (UP), Czechia, NANTES UNIVERSITE (UN), France, NANOTECH SOLUTIONS SOCIEDAD LIMITADA (NTSOL), Spain, CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL (Cogentech) Italy, MEDIZINISCHE UNIVERSITAET WIEN (MUW) Austria.
Project Officer: Roxana PAULOVICI
Official website: strike.unime.it

STRIKE-DN will raise excellence in research and training in nanomedicine/precision medicine creating new generation of entrepreneurial and innovative multidisciplinary doctoral candidates. New experimental aspects on design and synthesis of nanostructured magnetic materials will be applied to the development of innovative magnetic field-responsive nanotherapeutics for osteosarcoma (OS) combinational therapy. Moreover, the peculiar features of STRIKE nanomaterials will be exploited for liquid biopsy using biological samples of BRCA+ breast cancer (BC) patients. The cooperation among outstanding universities, research institutes and industries will provide the DCs with trans-national exchanges and the most innovative research trainings in novel anticancer therapeutic strategies, including in vivo biological evaluation, imaging in OS and early diagnosis in BC. STRIKE will provide enhanced career perspectives in academic and non-academic sectors for 8 DCs in highly innovative fields by interdisciplinary mobility among 12 institutes/companies in 8 EU countries. STRIKE aims to: 1) develop 8 highly skilled employable doctoral candidates; 2) enhance interdisciplinary capacity and cooperation within the EU nanomedicine and precision medicine research networks; 3) strengthen EU’s competitiveness and growth in nanomedicine and precision medicine through the translation of the consortium research/innovation outputs. The consortium will fulfill its goals through: a) achieving research excellence; b) providing a complete cutting-edge research and innovation training program with some of the European top research institutes and industry partners; c) hosting interdisciplinary and commercial workshops, seminars and outreach events; d) maximizing knowledge transfer using Open Science and patents; e) delivering highly trained professionals, whose profiles fit within the requirements of academia, industry and public/private institutions, fostering their employability and promoting the innovation of EU research.